Provectus Biopharmaceuticals Other Current Liabilities

Provectus Biopharmaceuticals (PVCT) currently reports a other current liabilities of $2.1M as of June 2026. That compares with $2.8M in the prior-year period — down 24.7% year over year. Use the charts on this page to explore Provectus Biopharmaceuticals's other current liabilities history and peer comparisons.

Provectus Biopharmaceuticals's other current liabilities decreased from $2.8M to $2.1M — a 24.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Provectus Biopharmaceuticals reported $2.1M in other current liabilities as of June 2026. That compares with $2.8M in the prior-year period — down 24.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $2.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Provectus Biopharmaceuticals, and consider following PVCT for alerts when major investors trade the stock.

Provectus Biopharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $2.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PVCT with unrelated industries.